Patents by Inventor Brian R. Petuch

Brian R. Petuch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cholesterol lowering compounds produced by directed biosynthesis
    Patent number: 5302604
    Abstract: Compounds of Structural Formula (I) ##STR1## are produced by directed biosynthesis. These compounds are squalene synthetase inhibitors and thus useful as cholesterol lowering agents, antifungal agents and cancer treatment agents.
    Type: Grant
    Filed: October 6, 1992
    Date of Patent: April 12, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Kevin M. Byrne, Shieh-Shung T. Chen, Louis Kaplan, John G. MacConnell, Brian R. Petuch, Raymond F. White, Byron H. Arison
  • Directed biosynthesis of biologically active compounds
    Patent number: 5294627
    Abstract: Compounds of Structural Formula (I) ##STR1## are produced by directed biosynthesis. These compounds are squalene synthase inhibitors and thus useful as cholesterol lowering agents and antifungal agents. These compounds are also inhibitors of farnesyl protein transferase and farnesylation of the oncogene protein Ras and thus useful in treating cancer.
    Type: Grant
    Filed: August 27, 1992
    Date of Patent: March 15, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Bryon H. Arison, Shieh-Shung T. Chen, Raymond F. White, Brian R. Petuch
  • Biotransformation process for the production of invermectin derivatives
    Patent number: 5250422
    Abstract: Incubation of 13.beta.-hydroxy ivermectin aglycone with a species of Bacillus subtilis or the incubation of 13-deoxy ivermectin aglycone with a mixed culture of a species of Bacillus subtilis and of Streptomyces griseus results in the production of 13-.beta. ivermectin monoglucopyranoside as the major product and of 5-.beta. ivermectin monoglucopyranoside as the minor product.
    Type: Grant
    Filed: May 11, 1992
    Date of Patent: October 5, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Brian R. Petuch, Edward S. Inamine, Shieh-Shung T. Chen, Raymond F. White, Byron H. Arison
  • Cyclcic FR-900520 microbial biotransformation agent
    Patent number: 5221625
    Abstract: Described is a process for producing a new immunosuppressant, a C-19/C-22 cyclic hemiketal (Compound I) biotransformation analog of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces sp. (Merck Culture Collection MA6963) ATCC No. 55230. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
    Type: Grant
    Filed: January 10, 1992
    Date of Patent: June 22, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Shieh-Shung T. Chen, Raymond F. White, Georgette Dezeny, Brian R. Petuch, George M. Garrity, Byron H. Arison, Amy M. Bernick
  • Antifungal agent
    Patent number: 5219985
    Abstract: A compound having the formula ##STR1## and a method of obtaining said compound is described. The compound has antifungal properties.
    Type: Grant
    Filed: October 31, 1990
    Date of Patent: June 15, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Brian R. Petuch, Byron H. Arison
  • Process for selectively acylating immunomycin
    Patent number: 5210030
    Abstract: Described is a new process for selectively acylating FK-506 type immunosuppressant macrolides, including immunomycin (FK-520), in the C-32 position, under novel conditions utilizing an immobilized lipase enzyme, an acyl donor, and a dry, non hydroxylic organic solvent. The enzyme is absorbed onto a solid support and the enzyme/support catalyzes the C-32 acylation. The enzyme/support complex can then be filtered from the reaction mixture and, recycled for use.
    Type: Grant
    Filed: June 25, 1990
    Date of Patent: May 11, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Brian R. Petuch, Shieh-shung T. Chen, Byron H. Arison
  • Phosphorylated cyclic lipopeptide
    Patent number: 5198421
    Abstract: There is disclosed a monophosphorylated cyclic lipopeptide compound obtained by biophosphorylating a cyclic lipopeptide related to echinocandins and having a peptide skeleton bearing several hydroxy groups wherein in the phosphorylated cyclic lipopeptide, the phosphate group is attached to the hydroxy group of the 4-hydroxyproline component of the lipopeptide. The compounds are useful for the control of fungi and parasites.
    Type: Grant
    Filed: April 26, 1991
    Date of Patent: March 30, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Shieh-Shung T. Chen, David J. Mathre, Brian R. Petuch, Robert A. Reamer
  • Novel avermectins are produced from known microorganisms
    Patent number: 5070015
    Abstract: Incubation of 13-deoxy ivermectin aglycone with a species of B. subtilis and of S. griseus results in the production of 13-.beta. ivermectin monoglucopyranoside as the major product and of 5-.beta. ivermectin monoglucopyranoside as the minor product.
    Type: Grant
    Filed: October 15, 1990
    Date of Patent: December 3, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Brian R. Petuch, Shieh-Shung T. Chen, Edward S. Inamine, Raymond F. White
  • Microbial transformation of simvastatin
    Patent number: 4997849
    Abstract: Compounds of formula (I) and (II): ##STR1## are HMG-CoA reductase inhibitors.
    Type: Grant
    Filed: June 23, 1989
    Date of Patent: March 5, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Brian R. Petuch, Byron H. Arison